AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24480899 — intervention group
Group type: COMPARATOR
Intervention: 14-week waiting list condition
Number of subjects: 121
Study 21842157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d,l‐methamphetamine
Number of subjects: 20
Study 21842157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19679580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19679580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (loading 3 microg kg(‐1) h(‐1) for 10 min; maintenance 0.2 microg kg(‐1) h(‐1) for 60 min)
Number of subjects: 12
Study 19679580 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose dexmedetomidine (loading 6 microg kg(‐1) h(‐1) for 10 min; maintenance 0.4 microg kg(‐1) h(‐1) for 60 min)
Number of subjects: 12
Study 19679580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (both doses)
Number of subjects: 12
Study 17430414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' daily ratings of mood and functional impairment
Number of subjects: 10
Study 17430414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' daily ratings of mood
Number of subjects: 10
Study 15601655 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based elemental feed (AAF) for 4 weeks
Number of subjects: 200
Study 15601655 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional rehabilitation (skimmed milk and then soya) for 4 weeks
Number of subjects: 200
Study 15601655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 200
Study 12167446 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 60
Study 12167446 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg) plus dexamethasone (8 mg)
Number of subjects: 60
Study 12167446 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 60
Study 10539742 — intervention group
Group type: COMPARATOR
Intervention: Sitostanol powder (1 g)
Number of subjects: 6
Study 10539742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol in lecithin micelles (700 mg)
Number of subjects: 6
Study 10539742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol in lecithin micelles (300 mg)
Number of subjects: 6
Study 8787461 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (37 degrees C)
Number of subjects: 60
Study 8787461 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (27 degrees C)
Number of subjects: 60
Study 2112906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based home care (n = 211)
Number of subjects: 419
Study 2112906 — intervention group
Group type: COMPARATOR
Intervention: Customary care (n = 208)
Number of subjects: 419
Study 7424927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg epinephrine hydrochloride
Number of subjects: 45
Study 7424927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg epinephrine hydrochloride
Number of subjects: 45
Study 7424927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg epinephrine hydrochloride
Number of subjects: 45
Study 7424927 — intervention group
Group type: COMPARATOR
Intervention: Control (0.1 mg and 0.3 mg)
Number of subjects: 45
Study 31699052 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with TAP block (40 mL of 0.375% ropivacaine)
Number of subjects: 65
Study 31699052 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 65
Study 30113724 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (80 mg)
Number of subjects: 40
Study 30113724 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (120 mg)
Number of subjects: 40
Study 30113724 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (180 mg)
Number of subjects: 40
Study 30113724 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (240 mg)
Number of subjects: 40
Study 30113724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27352504 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxa salt packets at Zhongwan (CV 12) combined with tropisetron hydrochloride (5 mg)
Number of subjects: 60
Study 27352504 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron hydrochloride (5 mg)
Number of subjects: 60
Study 24986113 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C30
Number of subjects: 224
Study 24986113 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS
Number of subjects: 224
Study 24986113 — intervention group
Group type: EXPERIMENTAL
Intervention: SCNS-SF34
Number of subjects: 224
Study 23237204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy in addition to orthoses therapy and home orientations
Number of subjects: 0
Study 23237204 — intervention group
Group type: COMPARATOR
Intervention: Orthoses therapy and home orientations
Number of subjects: 0
Study 20302573 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB-LED therapy (high-dose group)
Number of subjects: 20
Study 20302573 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB-LED therapy (low-dose group)
Number of subjects: 20
Study 20302573 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (lesion not treated with UVB-LED)
Number of subjects: 20
Study 18263937 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI >= 85 percentile)
Number of subjects: 1906
Study 18263937 — intervention group
Group type: COMPARATOR
Intervention: Non-obese group (BMI between 15 and 75 percentile)
Number of subjects: 1906
Study 15345158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg after induction and placebo at 12 h postoperatively
Number of subjects: 140
Study 15345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg after induction and 1.25 mg at 12 h postoperatively
Number of subjects: 140
Study 15345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg plus Metoclopramide 10 mg after induction and droperidol 1.25 mg at 12 h postoperatively
Number of subjects: 140
Study 11594643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme (cycling for up to 30 minutes three times weekly for 24-36 sessions over 12 weeks)
Number of subjects: 90
Study 11594643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Number of subjects: 90
Study 9855387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 153
Study 9855387 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 153
Study 9855387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 153
Study 8084354 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty
Number of subjects: 60
Study 8084354 — intervention group
Group type: COMPARATOR
Intervention: Open surgical commissurotomy
Number of subjects: 60
Study 2819572 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day diet control and oral dulcolax
Number of subjects: 74
Study 2819572 — intervention group
Group type: COMPARATOR
Intervention: Three-day diet control and enema
Number of subjects: 74
Study 811350 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal radiation therapy alone
Number of subjects: 51
Study 811350 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil alone
Number of subjects: 51
Study 811350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiation therapy and chlorambucil
Number of subjects: 51
Study 811350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 31532768 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal tDCS
Number of subjects: 41
Study 31532768 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 41
Study 28404609 — intervention group
Group type: EXPERIMENTAL
Intervention: Active moxibustion plus placebo gel
Number of subjects: 144
Study 28404609 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium gel plus placebo moxibustion
Number of subjects: 144
Study 25925431 — intervention group
Group type: EXPERIMENTAL
Intervention: BiClamp® forcep transection
Number of subjects: 96
Study 25925431 — intervention group
Group type: COMPARATOR
Intervention: Clamp crushing technique
Number of subjects: 96
Study 23703599 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster at K-D2 with prophylactic antiemetic
Number of subjects: 68
Study 23703599 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prophylactic ramosetron 0.3mg (Control)
Number of subjects: 68
Study 22059309 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention aimed at enhancing maternal responsivity, sensitivity, and childrearing behaviour over a period of 14 months starting from the third quarter of pregnancy.
Number of subjects: 24
Study 22059309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 24
Study 19407454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox (0.3‐42 mg/day)
Number of subjects: 62
Study 19407454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox (up to 18 mg/day) with intermediate steps
Number of subjects: 62
Study 19407454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox (combined group)
Number of subjects: 62
Study 19407454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 17035558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clubhouse model
Number of subjects: 170
Study 17035558 — intervention group
Group type: COMPARATOR
Intervention: PACT model
Number of subjects: 170
Study 14625336 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy
Number of subjects: 401
Study 14625336 — intervention group
Group type: COMPARATOR
Intervention: 15 days of antibiotic therapy
Number of subjects: 401
Study 14625336 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Number of subjects: 401
Study 14625336 — intervention group
Group type: COMPARATOR
Intervention: 15 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Number of subjects: 401
Study 14625336 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy (among patients with recurrent infections)
Number of subjects: 401
Study 14625336 — intervention group
Group type: COMPARATOR
Intervention: 15 days of antibiotic therapy (among patients with recurrent infections)
Number of subjects: 401
Study 16758733 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) level measurement using imunoluminometric assay (LUMItest) and immunochromatographic assay (PCT‐Q)
Number of subjects: 126
Study 16758733 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) level measurement on the first, second, and third day of hospitalization
Number of subjects: 126
Study 16758733 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) level measurement in sepsis caused by Gram positive and Gram negative bacteria
Number of subjects: 126
Study 16758733 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) as a diagnostic marker
Number of subjects: 126
Study 10556117 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill six-minute walk test (TM SMWT)
Number of subjects: 21
Study 10556117 — intervention group
Group type: COMPARATOR
Intervention: Hallway six-minute walk test (HW SMWT)
Number of subjects: 21
Study 10556117 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of HW SMWT and TM SMWT
Number of subjects: 21
Study 10556117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation and supplemental oxygen requirements
Number of subjects: 21
Study 10556117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-test variability of HW and TM SMWT
Number of subjects: 21
Study 8561059 — intervention group
Group type: COMPARATOR
Intervention: Fish oil supplement (15g) + 0 mg alpha-tocopheryl acetate (placebo)
Number of subjects: 48
Study 8561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + 100 mg alpha-tocopheryl acetate
Number of subjects: 48
Study 8561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + 200 mg alpha-tocopheryl acetate
Number of subjects: 48
Study 8561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + 400 mg alpha-tocopheryl acetate
Number of subjects: 48
Study 8561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g)
Number of subjects: 48
Study 8561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + alpha-tocopheryl acetate
Number of subjects: 48
Study 1927294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylidrin (13 women)
Number of subjects: 100
Study 1927294 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (12 women)
Number of subjects: 100
Study 1927294 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without uterine contractions
Number of subjects: 100
Study 1927294 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with preterm labor
Number of subjects: 100
Study 1927294 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who went into labor before the 37th gestational week
Number of subjects: 100
Study 7035687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin (5-day course)
Number of subjects: 51
Study 7035687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29680222 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal therapy associated with electromyographic biofeedback
Number of subjects: 22
Study 29680222 — intervention group
Group type: COMPARATOR
Intervention: Traditional vocal therapy (Placebo Group)
Number of subjects: 22
Study 28241822 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2482
Study 28241822 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2482
Study 28241822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study 26158679 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPs-HE intervention
Number of subjects: 1700
Study 26158679 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1700
Study 26158679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1700
Study 25003264 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (carbohydrate group)
Number of subjects: 11
Study 25003264 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin plus 15 g of glutamine (glutamine group)
Number of subjects: 11
Study 22984450 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements
Number of subjects: 16991
Study 19318465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Physical Activity (APA-stroke)
Number of subjects: 49
Study 19318465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 17319855 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 30
Study 17319855 — intervention group
Group type: COMPARATOR
Intervention: Standard consultations
Number of subjects: 30
Study 15031131 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cholesterol (total and HDL)
Number of subjects: 868
Study 15031131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure, gender, age, height, and heart rate
Number of subjects: 868
Study 11443472 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional ketamine 1 mg/kg IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Number of subjects: 55
Study 11443472 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional saline IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Number of subjects: 55
Study 11443472 — intervention group
Group type: COMPARATOR
Intervention: Placebo preincisional
Number of subjects: 55
Study 9709151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 40
Study 9709151 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 8032178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion with 2% pilocarpine, 1.5% carbachol, 0.25% timolol maleate, or 1% epinephrine every 12 hours
Number of subjects: 0
Study 8032178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion with 0.25% timolol and 1.5% carbachol every 12 hours
Number of subjects: 0
Study 8032178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion
Number of subjects: 0
Study 8032178 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% dipivefrin every 12 hours
Number of subjects: 0
Study 8032178 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially used antiglaucoma agents with nasolacrimal occlusion
Number of subjects: 0
Study 31784300 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide treatment for 24 weeks
Number of subjects: 0
Study 31784300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31515704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 270
Study 31515704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 27502413 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS (N=11)
Number of subjects: 21
Study 27502413 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (N=10)
Number of subjects: 21
Study 26602299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-specific water access and sanitation coverage assessment
Number of subjects: 13
Study 26602299 — intervention group
Group type: EXPERIMENTAL
Intervention: Random sample of households for sanitation coverage
Number of subjects: 13
Study 23764345 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (fitness sessions and education in healthful eating and physical activity)
Number of subjects: 91
Study 23764345 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (fitness sessions only)
Number of subjects: 91
Study 21531060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bono de Desarrollo Humano (BDH) cash transfer program
Number of subjects: 1196
Study 21531060 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no BDH)
Number of subjects: 1196
Study 18833170 — intervention group
Group type: EXPERIMENTAL
Intervention: Movalis injected into trigger points (3 injections + 15 mg tablets per day)
Number of subjects: 94
Study 18833170 — intervention group
Group type: EXPERIMENTAL
Intervention: Movalis intramuscular injection (3 injections + 15 mg tablets per day)
Number of subjects: 94
Study 18833170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 94
Study 16848149 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with propofol, fentanyl, and vecuronium (G1)
Number of subjects: 50
Study 16848149 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthesia with sevoflurane (G2)
Number of subjects: 50
Study 12635909 — intervention group
Group type: EXPERIMENTAL
Intervention: Message recipients who received a message favoring comprehensive exams
Number of subjects: 3
Study 12635909 — intervention group
Group type: EXPERIMENTAL
Intervention: Message recipients who received a message opposing comprehensive exams
Number of subjects: 3
Study 12635909 — intervention group
Group type: COMPARATOR
Intervention: Message recipients in conditions that elicited large amounts of thought
Number of subjects: 3
Study 12635909 — intervention group
Group type: COMPARATOR
Intervention: Message recipients in conditions that elicited small amounts of thought
Number of subjects: 3
Study 11049005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (25 mg)
Number of subjects: 269
Study 11049005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (50 mg)
Number of subjects: 269
Study 11049005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (75 mg)
Number of subjects: 269
Study 11049005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 11049005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (all doses)
Number of subjects: 269
Study 9093544 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy breakfast (over 20% of recommended daily energy intake)
Number of subjects: 195
Study 9093544 — intervention group
Group type: COMPARATOR
Intervention: Low energy breakfast (less than 10% of recommended daily energy intake)
Number of subjects: 195
Study 9093544 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy breakfast
Number of subjects: 195
Study 9093544 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake at breakfast (based on returned food)
Number of subjects: 195
Study 8509241 — intervention group
Group type: EXPERIMENTAL
Intervention: E85 (85% of IAT)
Number of subjects: 30
Study 8509241 — intervention group
Group type: EXPERIMENTAL
Intervention: E95 (95% of IAT)
Number of subjects: 30
Study 8509241 — intervention group
Group type: EXPERIMENTAL
Intervention: E100 (100% of IAT)
Number of subjects: 30
Study 8509241 — intervention group
Group type: EXPERIMENTAL
Intervention: E105 (105% of IAT)
Number of subjects: 30
Study 8509241 — intervention group
Group type: EXPERIMENTAL
Intervention: AT100 (100% of AT)
Number of subjects: 30
Study 2943752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 50 mg/day orally for 3 months
Number of subjects: 10
Study 2943752 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot preparation of LHRH superagonist (DTrp6‐LHRH) 3 mg intramuscularly approximately once a month for 3 months
Number of subjects: 10
Study 29608680 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion of β-lactams (4 hours)
Number of subjects: 105
Study 29608680 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion of β-lactams (30 minutes)
Number of subjects: 105
Study 27394386 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management counseling by telephone before and during pregnancy, with weekly contacts during the first 6 months and monthly contacts for the next 18 months. Unlimited access to a study website providing self-management tools.
Number of subjects: 0
Study 27394386 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0